Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC-Reference-Cited by-同舟云学术

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC

Published:2023-11 Issue:11 Volume:18 Page:1568-1580
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Soo Ross A.,Martini Jean-François,van der Wekken Anthonie J.,Teraoka Shunsuke,Ferrara Roberto,Shaw Alice T.,Shepard Deborah,Calella Anna Maria,Polli Anna,Toffalorio Francesca,Tomasini Pascale,Chiu Chao-Hua,Kowalski Dariusz M.,Kim Hye Ryun,Solomon Benjamin J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer;Gainor;Cancer Discov,2016

2. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models;Zou;Cancer Cell,2015

3. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial;Shaw;Lancet Oncol,2017

4. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study;Solomon;Lancet Oncol,2018

5. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2020

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance;JTO Clinical and Research Reports;2024-09

2. Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy;Oncology and Therapy;2024-07-22

3. SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study;Signal Transduction and Targeted Therapy;2024-07-15

4. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database;Journal of Thoracic Oncology;2024-07

5. Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease;Cancer Discovery;2024-06-03